Valuation Astellas Pharma Inc. OTC Markets

Stocks

ALPM.Y

US04623U1025

Pharmaceuticals

Market Closed - OTC Markets 22:58:27 09/10/2026 +03			5-day change	1st Jan Change
14.35 ^USD	+1.06%		+0.21%	+7.98%

10-08	Vir Biotechnology's VIR-5500 Gets FDA Fast Track Designation for Prostate Cancer	MT
10-08	Vir Biotechnology, Inc. and Astellas Pharma Inc. Announce FDAFast Track Designation for PSMA-Targeted Pro-XTEN® Dual-Masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer	CI

Company Valuation: Astellas Pharma Inc.

Data adjusted to current consolidation scope

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Market Cap ¹	3,519,738	3,381,409	2,946,773	2,589,390	4,512,563	4,029,798	-	-
Change	-	-3.93%	-12.85%	-12.13%	74.27%	-10.7%	-	-
Enterprise Value (EV) ¹	3,203,752	3,004,569	2,611,086	3,232,444	4,796,910	3,970,620	3,549,144	3,173,856
Change	-	-6.22%	-13.1%	23.8%	48.4%	-17.23%	-10.61%	-10.57%
P/E	28.5x	34.7x	173x	51x	15.5x	10.5x	11x	14.3x
PBR	2.39x	2.24x	1.85x	1.71x	2.47x	1.93x	1.75x	1.65x
PEG	-	-1.8x	-2.1x	0x	0x	0.3x	-2.23x	-0.6x
Capitalization / Revenue	2.72x	2.23x	1.84x	1.35x	2.11x	1.71x	1.83x	2.06x
EV / Revenue	2.47x	1.98x	1.63x	1.69x	2.24x	1.69x	1.61x	1.62x
EV / EBITDA	13.6x	12.6x	14.2x	13.5x	8.31x	5.36x	5.11x	5.37x
EV / EBIT	20.6x	22.6x	102x	78.8x	12.5x	7.9x	7.5x	8.69x
EV / FCF	14.1x	10.3x	-3.88x	20.5x	9.72x	8.58x	6.46x	6.15x
FCF Yield	7.08%	9.7%	-25.8%	4.87%	10.3%	11.7%	15.5%	16.3%
Dividend per Share ²	50	60	70	74	78	80.15	83.08	85.31
Rate of return	2.62%	3.19%	4.26%	5.12%	3.1%	3.57%	3.7%	3.8%
EPS ²	67.08	54.24	9.51	28.35	162.8	215	204.4	157.7
Distribution rate	74.5%	111%	736%	261%	47.9%	37.3%	40.6%	54.1%
Net sales ¹	1,296,163	1,518,619	1,603,672	1,912,323	2,139,245	2,355,201	2,200,069	1,957,078
EBITDA ¹	235,370	238,767	183,358	240,171	577,227	740,639	695,004	590,976
EBIT ¹	155,686	133,029	25,518	41,039	382,633	502,606	473,427	365,400
Net income ¹	124,086	98,714	17,045	50,747	291,535	369,771	348,527	265,536
Net Debt ¹	-315,986	-376,840	-335,687	643,054	284,347	-59,179	-480,654	-855,942
Reference price ²	1,911.00	1,883.00	1,643.50	1,446.50	2,519.00	2,247.50	2,247.50	2,247.50
Nbr of stocks (in thousands)	1,841,831	1,795,756	1,792,986	1,790,107	1,791,411	1,793,014	-	-
Announcement Date	4/27/22 A	4/27/23 A	4/25/24 A	4/25/25 A	4/27/26 A	-	-	-

¹JPY in Million²JPY

Estimates

P/E, Detailed evolution

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ELI LILLY AND COMPANY	33.55x	12.18x	25.21x	0.58%	1,051B
JOHNSON & JOHNSON	29.08x	6.43x	18.37x	2.04%	630B
ABBVIE INC.	35.19x	8.13x	16.76x	2.51%	489B
MERCK & CO., INC.	105.8x	5.93x	25.27x	2.34%	359B
ROCHE HOLDING AG	19.31x	4.72x	11.72x	2.8%	344B
NOVARTIS AG	20.06x	5.27x	12.98x	3.02%	272B
ASTRAZENECA PLC	20.57x	4.22x	12.06x	2.1%	246B
AMGEN INC.	26.34x	6.83x	12.21x	2.43%	224B
GILEAD SCIENCES, INC.	-45.84x	6.75x	26.31x	2.18%	187B
Average	27.12x	6.72x	17.88x	2.22%	422.63B
Weighted average by Cap.	32.41x	7.85x	19.34x	1.9%